According to Hovione, the United States Patent and Trademark Office (USPTO) has granted the company a patent for its XCAPs capsule-based dry powder inhaler. The European Patent Office granted the company a patent for the inhaler in September, 2013.
Hovione VP Peter Villax, who is a co-inventor of the DPI, commented, “We give our customers an edge in speed of development because we are perhaps the only independent company developing DPIs with expertise in every aspect of the inhaled drug development process. This patent grant in the US within 30 months of initial filing, underpins Hovione’s capabilities in innovation and intellectual property management, to successfully design, develop and deliver innovative products.”
Business Development Manager Gonçalo Andrade added, “The XCaps addresses a gap for a simple, easy to use, cost effective, multiple use, capsule based inhalation device. This allows our business partners to take advantage of additional patent protection for their inhalation drug product and effective drug product life cycle management.”
Hovione says that it currently has inhaled drug development projects underway with five pharmaceutical companies.
Read the Hovione press release.
